Drug news

NICE draft guidance recommends Olysio for Hepatitis C Genotype 1-Janssen Cilag

Read time: 1 mins

Last updated:18th Sep 2014

Published:18th Sep 2014

Source: Pharmawand

NICE (The National Institute for Health and Care Excellence) draft guidance recommends Olysio (simeprevir) from Janssen Cilag, in combination with peginterferon alfa and ribavirin as an option for treating genotype 1 Chronic Hepatitis C in adults. NICE has requested more information on the the use of Olysio in particular about whether the clinical effectiveness in people with genotype 1 can be generalised to those with genotype 4 Hepatitis C.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

CHMP positive recommendation to change to marketing authorisation of Triumeq (abacavir sulfate / dolutegravir sodium / lamivudine) to treat HIV infections.-ViiV HealthCare

1 mins

Drug news

CHMP positive recommendation to change the marketing authorisation of Sirturo (bedaquiline) in patients with pulmonary tuberculosis.- Jansssen- Cilag (J&J)

On 25 April 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Sirturo (bedaquiline). The marketing authorisation holder for this medicinal product is Janssen-Cilag International NV.

1 min

Drug news

CHMP positive recommendation to extend the marketing authorisation of Alecensa (alectinib hydrochloride).- Roche.

1 min

See all news